Newsfeeds Archive - Page 26 of 194

2 minute read

Ryman Hospitality Properties Late Tuesday Priced Upsized 3.5M Share Common Stock Offering @$93.25/Share

June 7, 5:33 AM

Ryman Hospitality Properties, Inc. (NYSE:RHP) (the "Company") today announced the upsizing and pricing of its previously announced underwritten registered public offering of shares of its common stock, par

RHP

1 minute read

Day One Late Tuesday Priced ~11,538M Share Public Offering of Common Stock @$13/Share

By Charles Gross

June 7, 5:29 AM

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases,

DAWN

1 minute read

Mondee Holding Earlier Priced Secondary Offering Of 5.25M Shares By Selling Stockholders @$10/Share

By Charles Gross

June 7, 5:09 AM

Mondee Holdings Inc. (NASDAQ:MOND) ("Mondee" or the "Company"), a technology-driven, next-generation marketplace, today announced the pricing of an underwritten offering of 5,250,000 shares of

MOND

1 minute read

Events
News

Janssen Announced First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma At ASCO

By Charles Gross

June 3, 2:40 PM

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific

JNJ

1 minute read

News

Gilead And Arcus Announced Anti-TIGIT Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study

By Charles Gross

June 3, 2:32 PM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer

GILD

1 minute read

Events
News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

By Charles Gross

June 2, 6:47 AM

BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX

2 minute read

News

MEDIROM Healthcare Technologies Announced Group Reorganization

By Charles Gross

June 2, 5:12 AM

MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that at a meeting of the Board of Directors held on

MRM

1 minute read

News

MEDIROM Healthcare Technologies Regains Compliance With NASDAQ Continued Listing Requirements

By Charles Gross

June 2, 5:08 AM

MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 1, 2023, the Nasdaq Hearing Panel (theMEDIROM Healthcare Technologies Inc.

MRM

1 minute read

News

Pfizer Announced Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial; Said Study Demonstrated Statistically Significant Reduction In Annualized Bleeding Rate Vs Prophylaxis, On-demand Intravenous Regimens

By Charles Gross

May 30, 6:48 AM

Pfizer Inc. (NYSE:PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically

PFE

1 minute read